MacroGenics Announces Date of First Quarter 2021 Financial Results Conference Call
Rhea-AI Summary
MacroGenics, Inc. (Nasdaq: MGNX) will release its first quarter 2021 financial results on April 29, 2021, after market close. A conference call is scheduled for the same day at 4:30 pm ET to discuss the results and corporate developments. Interested parties can join the call by dialing (877) 303-6253 for domestic or (973) 409-9610 for international access, using Conference ID# 5257004. The call will also be available via a listen-only webcast on the company's Investor Relations website, with a recorded replay accessible for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – MGNX
In the trading session that priced this news, MGNX gained 5.62%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, MD, April 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2021 after the market closes on Thursday, April 29, 2021. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, April 29, 2021 at 4:30 pm ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID# 5257004.
The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###